Published in Leukemia on November 27, 2008
Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res (2012) 1.73
Rib fractures and death from deletion of osteoblast βcatenin in adult mice is rescued by corticosteroids. PLoS One (2013) 1.39
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol (2012) 1.35
Immune complexes regulate bone metabolism through FcRγ signalling. Nat Commun (2015) 1.30
Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther (2010) 1.29
Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors. J Cell Biochem (2010) 1.26
Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol (2012) 1.21
Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL. Cancer Res (2010) 1.18
Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A (2014) 1.16
Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol (2010) 1.13
Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc (2010) 1.11
Prevention of progression in monoclonal gammopathy of undetermined significance. Clin Cancer Res (2009) 1.08
Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc (2016) 1.07
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res (2010) 1.07
Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood (2015) 1.04
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw (2009) 1.03
p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res (2012) 1.02
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res (2012) 0.96
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol (2016) 0.94
Cancer-associated bone disease. Osteoporos Int (2013) 0.94
Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther (2016) 0.93
The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther (2010) 0.93
Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma (2010) 0.93
Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma. Cancer Res (2016) 0.91
Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia (2012) 0.87
Fact or fiction--identifying the elusive multiple myeloma stem cell. J Hematol Oncol (2013) 0.86
Computational modeling of interactions between multiple myeloma and the bone microenvironment. PLoS One (2011) 0.86
Pasteurella multocida toxin-stimulated osteoclast differentiation is B cell dependent. Infect Immun (2010) 0.85
Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PLoS One (2012) 0.85
Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report. Eur Spine J (2012) 0.84
unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance? J Bone Miner Res (2014) 0.84
Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Rev Mol Diagn (2011) 0.84
A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors. BMC Cancer (2013) 0.83
Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. Oncotarget (2014) 0.83
Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease. Bone (2013) 0.83
Differential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma. Mol Cancer (2010) 0.83
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo. Leukemia (2016) 0.81
Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma. Leukemia (2014) 0.81
Bone-immune cell crosstalk: bone diseases. J Immunol Res (2015) 0.80
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment. Biomed Res Int (2016) 0.79
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. Oncologist (2011) 0.78
Role and mechanism of action of sclerostin in bone. Bone (2016) 0.78
Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression. PLoS One (2013) 0.78
Role of osteocytes in multiple myeloma bone disease. Curr Opin Support Palliat Care (2014) 0.78
Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease. BMC Genomics (2014) 0.78
Myeloma bone disease. J Bone Miner Res (2009) 0.77
The first Tianjin, China forum on tumor microenvironment. Cancer Res (2011) 0.77
Dkk-1 and IL-7 in plasma of patients with multiple myeloma prevent differentiation of mesenchymal stem cells into osteoblasts. Am J Blood Res (2014) 0.77
In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease. PLoS One (2012) 0.77
Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche. J Leukoc Biol (2017) 0.77
Identify multiple myeloma stem cells: Utopia? World J Stem Cells (2015) 0.76
Understanding the multiple biological aspects leading to myeloma. Haematologica (2014) 0.76
Evolutionary Dynamics of Tumor-Stroma Interactions in Multiple Myeloma. PLoS One (2016) 0.76
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20. Leukemia (2015) 0.75
Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma. Sci Transl Med (2016) 0.75
A quantitative method for the characterization of lytic metastases of the bone from radiographic images. ScientificWorldJournal (2014) 0.75
Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma. Clin Cancer Res (2016) 0.75
Mandibular destructive radiolucent lesion: The first sign of multiple myeloma. J Clin Exp Dent (2016) 0.75
Simvastatin Protects Osteoblasts from the Deleterious Effects of the Liquid Milieu of Multiple Myeloma. West Indian Med J (2015) 0.75
Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors. Bone (2013) 0.75
Assessment of whole body MRI and sestamibi technetium-99m bone marrow scan in prediction of multiple myeloma disease progression and outcome: a prospective comparative study. BMJ Open (2013) 0.75
A man with a fracture from minor trauma. World J Emerg Med (2014) 0.75
The effects of proteasome inhibitors on bone remodeling in multiple myeloma. Bone (2016) 0.75
Role of Wnt/β-catenin pathway in inducing autophagy and apoptosis in multiple myeloma cells. Oncol Lett (2016) 0.75
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation. Oncotarget (2017) 0.75
Dectin-1 signaling inhibits osteoclastogenesis via IL-33-induced inhibition of NFATc1. Oncotarget (2017) 0.75
Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway. Oncotarget (2017) 0.75